| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
No pharmacodynamic target for the labelled form; the unlabelled parent sulfabenzamide inhibits bacterial dihydropteroate synthase (DHPS) in the folate pathway, but the d4 isotopologue is used analytically for isotope-dilution quantification rather than for target-based pharmacology.
|
|---|---|
| ln Vitro |
In the process of developing new drugs, stable heavy isotopes of carbon, hydrogen, and other elements have been added to pharmacological molecules, mostly as quantitative tracers. Due to its potential effects on medication pharmacokinetics and metabolic properties, deuteration is a matter for worry [75].
Not applicable as a drug; the labelled standard’s performance is defined by isotopic purity, chromatographic co-elution with the unlabelled analyte, and ionization efficiency in LC-MS/MS, with the deuterium label providing a distinct mass transition for reliable quantification. |
| ln Vivo |
No therapeutic in vivo activity; the compound is used as a tracer/internal standard in residue-depletion and pharmacokinetic studies of sulfabenzamide, not as an independent therapeutic, and its in vivo behaviour is assessed only as part of bioanalytical method validation.
|
| Enzyme Assay |
No target-based binding assay; in bioanalytical workflows the d4 standard is spiked into blank matrix (plasma, tissue, milk, honey), extracted by protein precipitation or QuEChERS, and quantified by LC-MS/MS against a calibration curve, with recovery and matrix-effect validation.
|
| Cell Assay |
No cell-based pharmacology is defined; the standard is spiked into cell-culture supernatants or lysates solely for quantification of sulfabenzamide, and any cellular effects would be attributed to the unlabelled parent rather than the isotopologue.
|
| Animal Protocol |
No in vivo pharmacology protocol exists; in residue or PK studies the d4 standard is added at the extraction step to plasma/tissue samples collected after sulfabenzamide dosing, and concentrations are calculated by isotope-dilution LC-MS/MS, with pilot method validation for linearity, accuracy and precision.
|
| References |
| Exact Mass |
280.082
|
|---|---|
| CAS # |
2732981-22-3
|
| Related CAS # |
Sulfabenzamide;127-71-9
|
| PubChem CID |
169446588
|
| Appearance |
White to off-white solid
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
402
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C(C(=C1N)[2H])[2H])S(=O)(=O)NC(=O)C2=CC=CC=C2)[2H]
|
| InChi Key |
PBCZLFBEBARBBI-YKVCKAMESA-N
|
| InChi Code |
InChI=1S/C13H12N2O3S/c14-11-6-8-12(9-7-11)19(17,18)15-13(16)10-4-2-1-3-5-10/h1-9H,14H2,(H,15,16)/i6D,7D,8D,9D
|
| Chemical Name |
N-(4-amino-2,3,5,6-tetradeuteriophenyl)sulfonylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
